Due to the debatable negative impact attributed to KIT mutation, CBF AML with KIT mutation was formerly assigned to the intermediate category, whereas more recent guidelines only stated that prognosis may be less favorable than CBF AML without such a mutation. This evidence concerns the gene KIT and acute myeloid leukemia.